Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer

Yoshino, Ichiro; Yokoyama, Hideki; Yano, Tokujiro; Ueda, Takashi; Takai, Eiji; Mizutani, Kazuki; Asoh, Hiroshi; Ichinose, Yukito

doi:10.1016/0003-4975(96)00470-5

Cited by 89 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such so-called "skip lesions" confer a prognosis more like N1 disease than N2 disease, [11][12][13] and SLN mapping may lead to a more accurate determination of prognosis in such patients. In addition, in patients who have aberrant lymphoid drainage, the true SLN may not be resected during surgery, leading to a pathologic stage of N0 when LN disease actually was left behind at surgery.…”

mentioning

confidence: 99%

Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma

Pulte

Crawford

et al. 2005

Cancer

View full text Add to dashboard Cite

An overview on all hydrogen‐bonded helix types, which can be expected in the novel class of β/δ‐hybrid peptides, is provided on the basis of ab initio molecular orbital theory. The results show a considerable potential of different folding patterns, which makes this novel class of peptide foldamers interesting for peptide and protein design. Thus, this study may stimulate the synthesis of such hybrid peptides. The large number of helix types found for β/δ‐hybrid peptides together with the many helices experimentally found and theoretically predicted in the other classes of peptide and hybrid peptide foldamers provide a good basis to establish general correspondence rules for their mutual exchange in peptide sequences. This is done by introduction of the concept of pattern and shape correspondence. © 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 94: 279–291, 2010. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

show abstract

mentioning

confidence: 99%

Sentinel lymph node mapping and molecular staging in nonsmall cell lung carcinoma

Pulte

Crawford

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…However, Tanaka et al [13] compared the five-year survival rates of sN2 patients and nsN2 patients, and found no significant difference. Similarly, Yoshino et al [10] reported no statistically significant difference, although the five-year survival rates of the patients with and without sN2 were 35% and 13%, respectively. In our study, similarly, we found that the five-year overall survival rate was higher in sN2 patients; however, it did not reach statistical significance.…”

Section: Discussionmentioning

confidence: 84%

“…Furthermore, the histological type was reported to have no effect on the long-term survival in the studies by Yoshino et al [10] and Gunluoglu et al [11] between the long-term survival and tumor histology of sN2 patients and nsN2 patients. Nevertheless, there is no consensus about the presence of a predominant histological type in sN2 patients.…”

Section: Discussionmentioning

confidence: 96%

“…Nevertheless, there is no consensus about the presence of a predominant histological type in sN2 patients. [8,[10][11][12] Squamous-cell carcinomas are more common in the sN2 group in several studies, [5,13,14] whereas the incidence of adenocarcinomas is higher in the other studies. [3,8,10] The squamous-cell carcinomas were reported to cause sN2 more commonly in our patient group; however, we found no statistically significant difference in the sN2 rates between the squamous-cell carcinomas and adenocarcinomas.…”

Section: Discussionmentioning

confidence: 99%

“…[5,10,[15][16][17] Riquet et al [8] showed that the five-year survival outcomes were significantly higher in patients with skip metastases. However, Tanaka et al [13] compared the five-year survival rates of sN2 patients and nsN2 patients, and found no significant difference.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Skip metastasis in non-small cell lung cancer: does it affect the prognosis?

Akçay¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

ÖZAmaç: Bu çalışmada küçük hücreli dışı akciğer kanseri nedeni ile rezeksiyon yapılan hastalarda skip metastazları incelendi. Çalışma planı: Kliniğimizde Ocak 2005 -Aralık 2011 tarihleri arasında küçük hücreli dışı akciğer kanseri tanısı konan ve R0 akciğer rezeksiyonu örneklerinin patolojik incelemesi sonucunda aynı taraf mediastinal lenf nodu metastazı saptanan toplam 111 hasta (94 erkek, 17 kadın; ort. yaş: 58.9±10.2 yıl; dağılım 35-82 yıl) retrospektif olarak incelendi. Hastalar skip metastazlı grup (sN2) (grup 1, n=55) [N1(-), N2(+)] ve skip metastazı olmayan aynı taraf mediastinal lenf nodu metastazlı grup (nsN2) (grup 2, n=56) [N1(+), N2(+)] olmak üzere iki gruba ayrıldı. Bul gu lar: Her iki çalışma grubunda medyan sağkalım 25 ay olup, beş yıllık genel sağkalım oranı %13 idi. Beş yıllık genel sağkalım oranı grup 2'ye kıyasla grup 1'de daha yüksek olmakla birlikte (sırasıyla %7.4'e karşın %20), fark istatistiksel olarak anlamlı değildi (p=0.084). Sonuç: Çalışma sonuçlarımız istatistiksel olarak anlamlı bir fark olmasa da skip metastazı olmayan hastalara kıyasla, skip metastazlı ameliyat edilebilir hastalarda beş yıllık genel sağkalım oranının daha yüksek olduğunu göstermektedir.Anahtar sözcükler: Mediastinal lenf nodu; küçük hücreli dışı akciğer kanseri; skip metastazı. ABSTRACTBackground: This study aims to examine skip metastases in patients who had resection due to non-small cell lung cancer. Methods: A total of 111 patients (94 males, 17 females; mean age: 58.9±10.2 years; range 35 to 82 years) who were diagnosed with non-small cell lung cancer and in whom an ipsilateral mediastinal lymph node metastasis was detected based on the pathological examination of the R0 pulmonary resection samples between January 2005 and December 2011 in our clinic were retrospectively analyzed. The patients were divided into two groups: the skip metastasis group (sN2) (group 1, n=55) [N1(-), N2(+)] and non-skip ipsilateral mediastinal lymph node metastasis group (nsN2) (group 2, n=56) [N1(+), N2(+)]. Results: The median survival was 25 months and fiveyear overall survival rate was 13% for both study groups. Five-year overall survival rate was higher in group 1, compared to group 2 (20% vs. 7.4%, respectively), although the difference was not statistically significant (p=0.084). Conclusion: Our study results show that five-year overall survival rates of operable patients with skip metastases are higher than those without skip metastases, although the difference is not statistically significant.

show abstract